Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Healthc Patient Saf. 2011;3:107-19. doi: 10.2147/DHPS.S24106. Epub 2011 Dec 22.

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.

Author information

1
Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.

Abstract

Androgen deprivation therapy (ADT) is the most effective systemic treatment for prostate cancer. ADT has been shown to have a high rate of response and to improve overall survival in patients with metastatic prostate cancer. In addition, multiple studies have shown that adding ADT to external beam radiation therapy leads to improvement in cure rates and overall survival in prostate cancer patients. The most commonly used ADT is gonadotropin-releasing hormone (GnRH) agonist therapy. Although GnRH agonist therapy has significant benefits for patients with prostate cancer, it has also been shown to have significant side effects, including fatigue, hot flashes, decreased libido, decreased quality of life, obesity, diabetes mellitus, coronary artery disease, decreased bone mineral density, and increased risk of fractures. Therefore, it is crucial that the benefits of ADT be weighed against its potential adverse effects before its use.

KEYWORDS:

androgen deprivation therapy; gonadotropin-releasing hormone agonists; prostate cancer

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center